MX2012004259A - Combinacion. - Google Patents

Combinacion.

Info

Publication number: MX2012004259A
Authority: MX; Mexico
Prior art keywords: pharmaceutically acceptable; acceptable salt; treatment; relates; cancer
Prior art date: 2009-10-12

Application number

MX2012004259A

Other languages

English (en)

Spanish (es)

Inventor

Tona Gilmer

Shannon Renae Morris

Sylvie Laquerre

Kurtin Earl Bachman

Joel David Greshock

Kurt Auger

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-12

Filing date

2010-10-12

Publication date

2012-05-29

2010-10-12 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2012-05-29 Publication of MX2012004259A publication Critical patent/MX2012004259A/es

Links

238000000034 method Methods 0.000 abstract 3
206010028980 Neoplasm Diseases 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
229940124647 MEK inhibitor Drugs 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
229940116355 PI3 kinase inhibitor Drugs 0.000 abstract 1
METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 abstract 1
239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MX2012004259A 2009-10-12 2010-10-12 Combinacion. MX2012004259A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25063509P	2009-10-12	2009-10-12
PCT/US2010/052242 WO2011046894A1 (en)	2009-10-12	2010-10-12	Combination

Publications (1)

Publication Number	Publication Date
MX2012004259A true MX2012004259A (es)	2012-05-29

Family

ID=43876468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2012004259A MX2012004259A (es)	2009-10-12	2010-10-12	Combinacion.

Country Status (13)

Country	Link
US (1)	US20120202822A1 (2)
EP (1)	EP2488184A4 (2)
JP (1)	JP2013507442A (2)
KR (1)	KR20120097496A (2)
CN (1)	CN102665720A (2)
AU (1)	AU2010307043C1 (2)
BR (1)	BR112012008519A2 (2)
CA (1)	CA2777561A1 (2)
EA (1)	EA020965B1 (2)
IL (1)	IL219103A0 (2)
MX (1)	MX2012004259A (2)
WO (1)	WO2011046894A1 (2)
ZA (1)	ZA201202416B (2)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2013545756A (ja) *	2010-11-16	2013-12-26	グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド	投与および治療方法
JP6342396B2 (ja)	2012-08-07	2018-06-13	ノバルティスアーゲー	Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
KR20190057421A (ko)	2012-08-17	2019-05-28	에프. 호프만-라 로슈 아게	코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
CN103936728B (zh) *	2013-01-18	2016-08-10	通化济达医药有限公司	噻唑激酶抑制剂
CN103936730A (zh) *	2013-01-22	2014-07-23	通化济达医药有限公司	苯磺酰胺噻唑激酶抑制剂
CN103965180B (zh) *	2013-01-24	2016-09-07	通化济达医药有限公司	苯磺酰胺噁唑和噻唑激酶抑制剂
US20150352121A1 (en) *	2013-03-12	2015-12-10	Glaxosmithkline Llc	Combination
MA38522A1 (fr)	2013-03-21	2017-10-31	Novartis Ag	Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.
WO2015003571A1 (zh) *	2013-07-08	2015-01-15	杭州普晒医药科技有限公司	达拉菲尼甲磺酸盐的新晶型及其制备方法
US11007183B2 (en) *	2013-12-20	2021-05-18	Biomed Valley Discoveries, Inc.	Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2349832A1 (en) *	1999-01-13	2000-07-20	Warner-Lambert Company	Benzenesulfonamide derivatives and their use as mek inhibitors
US8835473B2 (en) *	2004-04-16	2014-09-16	Rutgers, The State University Of New Jersey	Methods and compositions for treating cancer
US7691377B2 (en) *	2004-04-16	2010-04-06	Rutgers, The State University Of New Jersey	Methods and compositions for treating melanoma
WO2007084391A2 (en) *	2006-01-18	2007-07-26	Amgen Inc.	Thiazole compounds as protein kinase b ( pkb) inhibitors
PE20090717A1 (es) *	2007-05-18	2009-07-18	Smithkline Beecham Corp	Derivados de quinolina como inhibidores de la pi3 quinasa
UA103319C2 (en) *	2008-05-06	2013-10-10	Глаксосмитклайн Ллк	Thiazole- and oxazole-benzene sulfonamide compounds

2010
- 2010-10-12 EP EP20100823916 patent/EP2488184A4/en not_active Withdrawn
- 2010-10-12 MX MX2012004259A patent/MX2012004259A/es active IP Right Grant
- 2010-10-12 KR KR1020127011760A patent/KR20120097496A/ko not_active Withdrawn
- 2010-10-12 US US13/501,387 patent/US20120202822A1/en not_active Abandoned
- 2010-10-12 CN CN2010800564396A patent/CN102665720A/zh active Pending
- 2010-10-12 JP JP2012534272A patent/JP2013507442A/ja not_active Ceased
- 2010-10-12 WO PCT/US2010/052242 patent/WO2011046894A1/en not_active Ceased
- 2010-10-12 BR BR112012008519A patent/BR112012008519A2/pt not_active IP Right Cessation
- 2010-10-12 CA CA2777561A patent/CA2777561A1/en not_active Abandoned
- 2010-10-12 EA EA201270537A patent/EA020965B1/ru not_active IP Right Cessation
- 2010-10-12 AU AU2010307043A patent/AU2010307043C1/en not_active Ceased
2012
- 2012-04-03 ZA ZA2012/02416A patent/ZA201202416B/en unknown
- 2012-04-05 IL IL219103A patent/IL219103A0/en unknown

Also Published As

Publication number	Publication date
ZA201202416B (en)	2012-12-27
EP2488184A1 (en)	2012-08-22
AU2010307043C1 (en)	2014-03-13
AU2010307043A1 (en)	2012-05-17
EP2488184A4 (en)	2013-04-24
JP2013507442A (ja)	2013-03-04
IL219103A0 (en)	2012-06-28
EA201270537A1 (ru)	2012-12-28
CA2777561A1 (en)	2011-04-21
BR112012008519A2 (pt)	2016-04-05
CN102665720A (zh)	2012-09-12
KR20120097496A (ko)	2012-09-04
AU2010307043B2 (en)	2013-10-31
EA020965B1 (ru)	2015-03-31
US20120202822A1 (en)	2012-08-09
WO2011046894A1 (en)	2011-04-21

Legal Events

Date	Code	Title	Description
2015-01-20	FG	Grant or registration

Publication	Publication Date	Title
MX2012004259A (es)	2012-05-29	Combinacion.
RU2016141569A (ru)	2018-04-26	Комбинации
NZ610746A (en)	2015-06-26	Methods of treatment using selective bcl-2 inhibitors
MX2015016592A (es)	2016-03-16	Combinaciones de un anticuerpo anti-pd-l1 y un inhibidor de mek y/o un inhibidor de raf-b.
CL2014000492A1 (es)	2014-10-03	Compuestos derivados de n-[3-(1,2,4-oxadiazol-(5-il/amino/carbamoil)fenil]imidazo[1,2-a]pirdina-3-carboxamida, inhibidores de la quinasa c-kit; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, artritis, aterosclerosis, entre otras
UA114906C2 (uk)	2017-08-28	Гетероциклільні сполуки як інгібітори мек
EA201290149A1 (ru)	2012-11-30	Комбинация
WO2020115555A3 (en)	2020-08-06	Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
MX343014B (es)	2016-10-20	Sales y formas cristalinas de un agente inductor de apoptosis.
MX2016007653A (es)	2016-10-13	Combinaciones de trametinib, panitumumab y dabrafenib para el tratamiento del cancer.
WO2014066606A8 (en)	2015-06-04	Combination
TW200738729A (en)	2007-10-16	Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
PH12014500809A1 (en)	2014-05-26	Polymorphs of arry-380, a slective herb2 inhibitor and pharmaceutical compositions containing them
WO2016109217A3 (en)	2016-08-25	Btk inhibitors
WO2018183089A8 (en)	2018-11-22	Compositions for treating and/or preventing cancer
PH12013501098A1 (en)	2013-07-08	Pharmaceutical compositions
PH12017501121B1 (en)	2017-11-27	Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors
WO2014027981A3 (en)	2014-04-03	Effervescent tablet formulations of dapoxetine and a pde5 inhibitor
WO2011038380A3 (en)	2011-09-15	Combination
WO2013117503A3 (en)	2013-10-03	Pi3k inhibitors for treating fibrotic diseases
PT3774795T (pt)	2022-07-20	4-(1h-imidazol-5-il)-1h-pirrolo[2,3-b]piridinas para utilização no tratamento de leucemias, linfomas e tumores sólidos
IN2015DN02667A (2)	2015-09-04
EA201290339A1 (ru)	2012-12-28	Комбинация
EA201500882A1 (ru)	2016-05-31	Комбинация
FI3765012T3 (fi)	2026-04-17	Dgat1-inhibiittoreita ummetuksen hoitoon